Journals / Uludağ Üniversitesi Tıp Fakültesi Dergisi / 2017 / Cilt: 43 - Sayı: 3

Thalassemia Intermedia

Talasemi İntermedia

Pages
141–145
Publication Date
2017-09-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

For these problems, we want to mention iron chelation therapy, splenectomy, gall stones, hypercoagulability, pulmonary hypertension, growth retardation and other endocrine complications of these patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Beta-thalassemias are a group of hereditary blood disorders characterized by anomalies in the synthesis of the beta chains of hemoglobin, impaired alfa beta globin ratio, ineffective erythropoiesis and chronic anemia resulting in variable phenotypes ranging from severe anemia and transfusion dependency to clinically asymptomatic individuals.
📊
Key Findings & Data:Recent studies show that thalassemia intermedia is not as harmless as we think and is associated with organ dysfunctions, complications and high morbidity rate.
💡
Conclusion & Impact:For these problems, we want to mention iron chelation therapy, splenectomy, gall stones, hypercoagulability, pulmonary hypertension, growth retardation and other endocrine complications of these patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Globin defekti. Talasemi. Talasemi intermedia · Globin pathology. Thalassemia. Thalassemia intermedia

Abstract

Beta-thalassemias are a group of hereditary blood disorders characterized by anomalies in the synthesis of the beta chains of hemoglobin, impaired alfa beta globin ratio, ineffective erythropoiesis and chronic anemia resulting in variable phenotypes ranging from severe anemia and transfusion dependency to clinically asymptomatic individuals. The term thalassemia intermedia refers to patients with clinical symptoms which are too mild than thalassemia major and too severe than thalassemia minor. Recent studies show that thalassemia intermedia is not as harmless as we think and is associated with organ dysfunctions, complications and high morbidity rate. For these problems, we want to mention iron chelation therapy, splenectomy, gall stones, hypercoagulability, pulmonary hypertension, growth retardation and other endocrine complications of these patients.

Özet

Beta talasemi hastalığı beta globin zincirlerinin sentezindeki bozukluk, alfa ve beta zincir dengesizliği, etkin olmayan eritropoez ve kronik aneminin sonucu gelişir. Talasemide klinik bulgu oldukça değişkendir, bir uçta hiçbir klinik bulgusu olmayan taşıyıcı bireyler var iken, diğer uçta yaşamının birinci yılından itibaren derin anemi nedeni ile düzenli transfüzyon gereksinimi olan ağır seyirli hastalar olabilir. Beta talasemi intermedia klinikte talasemi minörden ağır, fakat talasemi majörden hafif hastaları tanımlamak için kullanılmaktadır. Yapılan son çalışmalar talasemi intermedianın düşünülenin aksine çok da hafif seyretmediğini, organ işlev bozuklukları ve komplikasyonlarla ilişkili olduğunu göstermiştir. Biz de bu nedenle, bu grup talasemi hastalarına dikkat çekerek, olguların tanı ve izlemini (kan transfüzyon ve demir şelasyon tedavisi, splenektomi, safra taşları, tromboemboliye yatkınlık, pulmoner hipertansiyon, büyüme gelişme geriliği ve diğer endokrin yan etkiler) tartışmayı hedefledik.

🔖

Cite This Article

CELKAN, T., KIZILOCAK, H. (2017). Thalassemia Intermedia. Uludağ Üniversitesi Tıp Fakültesi Dergisi, Cilt: 43 - Sayı: 3, 141–145. https://ajindex.com/articles/134738

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...